2025-05-19-Jefferies-卫材（4523）_因利润率缩窄下调盈利预期和目标价；重申持有评级_10页_371kb

Eisai Summary: Cutting Profit Estimates and PT on Shrinking Margins; Reiterate Hold

Core Content

Eisai Co., Ltd. is a pharmaceutical company that produces and sells prescription drugs and medical equipment. The company's performance and future outlook have been analyzed by Jefferies, leading to a revised investment recommendation and price target.

Main Points

• Profit Estimates Cut: Jefferies has significantly reduced its estimates of Eisai's future profits following the release of disappointing FY3/26 guidance.
• Shrinking Margins: Eisai's gross margin (GPM) is expected to continue declining due to the increasing proportion of Leqembi sales in its revenue. The GPM is projected to fall from 78.6% to 76.9% this year, and the trend is anticipated to continue.
• Consensus Estimates Too Ambitious: The current consensus for operating profit margin (OPM) is seen as overly optimistic. Jefferies forecasts a lower OPM than the FactSet consensus, which is expected to rise to 9.3% in FY3/28 and 10.5% in FY3/29.
• SubCu Leqembi Impact: The potential approval of the subcutaneous formulation of Leqembi may lead to higher costs (COGS) and further margin compression.
• Price Target and Rating: Jefferies has cut its DCF-derived price target (PT) to ¥3,600, representing a potential 5% downside from the previous PT of ¥4,200. The rating has been reiterated as Hold.
• Investment Thesis: Leqembi is the key driver of Eisai's profitability. However, the company's peak sales estimates for Leqembi are much lower than the Visible Alpha consensus, suggesting a more conservative outlook.
• Valuation and Multiples: The valuation methodology includes DCF, assuming a WACC of 5% and a terminal growth rate of 0%. Key multiples such as P/E, P/B, and EV/EBITDA are presented for various fiscal years.
• Risks: The primary risks include commercial failure of Leqembi, underperformance of Lenvima sales, and regulatory changes affecting pricing in major markets. On the positive side, overperformance of Leqembi could lead to strong share price gains.
• Company Fundamentals: Eisai's sales are expected to decline in certain segments, while others may remain stable or grow. The company's financial health, as reflected in cash flow and balance sheet, shows a mix of positive and negative trends.
• ESG Initiatives: Eisai aims to increase the proportion of women managers and younger Director-level managers, reflecting a commitment to diversity and inclusion.

Key Information

Financial Projections

Price Target and Investment Thesis

• Price Target: ¥3,600 (from ¥4,200), a 5% downside.
• Investment Thesis: Leqembi is the main swing factor, with Jefferies estimating global peak sales of about ¥264bn by FY3/34, significantly lower than the Visible Alpha consensus of ¥519bn.
• Risk/Reward:
  • Base Case: ¥3,600 (downside of 5%)
  • Upside Scenario: ¥4,400 (if WACC is 4%)
  • Downside Scenario: ¥3,100 (if WACC is 6%)

Key Multiples and Ratios

ESG and Management Initiatives

• Increase the proportion of women managers to 30% from 11% in April 2021.
• Increase the proportion of Director-level managers in their 30s or younger to 20% from 10% in April 2021.

Analysts

• Stephen Barker and Miyabi Yamakita are the equity analysts who provided the analysis.
• Both analysts are employed by Jefferies (Japan) Limited, a non-US affiliate, and are not registered with FINRA.

Investment Recommendation

• Hold: Indicates that the company is expected to provide a total return of plus 15% or minus 10% within 12 months.

Valuation Methodology

Jefferies uses a variety of methods to determine its price targets, including DCF, EBITDA, EPS, and other financial metrics.

Risks

• Commercial Failure: Leqembi's failure could severely impact the company's financials.
• Regulatory Changes: Affecting pricing in large markets like the US could lead to reduced profits.
• Currency Risk: The price target is in Japanese Yen, and fluctuations in exchange rates could impact returns for non-Japanese investors.

Summary

Jefferies has cut its profit estimates and price target for Eisai due to shrinking margins and the continued reliance on Leqembi, which is expected to grow as a proportion of revenue but may also cause margin compression. The company's financials show a mix of declining and stable sales, with the investment thesis centered around the performance of Leqembi. The analysts reiterate a Hold rating, with a revised PT of ¥3,600, representing a potential 5% downside. The report highlights the importance of ESG initiatives and the risks associated with regulatory changes and currency fluctuations.